Oxford Immunotec (OXFD) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Oxford Immunotec Reports First Quarter 2017 Financial Results
May 2, 2017 7:00 AM EDTFirst quarter revenue of $21.5 million, an increase of 26% compared to prior year periodFirst quarter Tuberculosis revenue of $18.5 million, an increase of 8% compared to prior year periodFirst quarter Tick-borne disease and other revenue of $3.0 million
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 02, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced first quarter 2017 financial results.
We are very pleased with our performance during the... More
